Stock Traders Buy High Volume of Call Options on Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw some unusual options trading on Tuesday. Investors acquired 2,940 call options on the company. This is an increase of 49% compared to the typical daily volume of 1,968 call options.

Soleno Therapeutics Price Performance

SLNO opened at $33.48 on Wednesday. The stock’s 50 day simple moving average is $38.07 and its 200 day simple moving average is $48.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55. Soleno Therapeutics has a 1 year low of $29.43 and a 1 year high of $90.32. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 145.57 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. As a group, analysts predict that Soleno Therapeutics will post -3.72 earnings per share for the current year.

Institutional Investors Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. Raymond James Financial Inc. bought a new stake in Soleno Therapeutics in the 2nd quarter worth $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics in the third quarter valued at about $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Soleno Therapeutics during the third quarter valued at about $37,000. Global Retirement Partners LLC boosted its holdings in shares of Soleno Therapeutics by 519.0% during the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after purchasing an additional 519 shares during the period. Finally, Quarry LP purchased a new stake in shares of Soleno Therapeutics during the third quarter worth about $47,000. 97.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

SLNO has been the subject of several research reports. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research note on Tuesday, January 13th. Oppenheimer decreased their price target on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. HC Wainwright lowered their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a report on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Soleno Therapeutics has an average rating of “Moderate Buy” and an average price target of $102.00.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Unusually large options activity today — nearly 2,940 call options traded (about a 49% rise vs. average). That suggests short‑term bullish/speculative positioning or hedging that can drive intraday buying and volatility.
• Positive Sentiment: Recent fundamental support: Soleno reported a Q4 (Feb. 25) beat on EPS and revenue, which may underpin some investor confidence despite mixed forward guidance. (No new earnings report today.)
• Neutral Sentiment: Multiple law firms are issuing deadline reminders for investors to seek lead‑plaintiff status (May 5, 2026). These notices increase publicity around the litigation but are routine in securities cases. ROSEN reminder
• Negative Sentiment: Hagens Berman filed a securities class action alleging investors were misled about DCCR (VYKAT™ XR) after Soleno’s Nov. 5, 2025 disclosure of disappointing drug information. This is a direct legal filing that can increase potential liability and reputational risk. Hagens Berman filing
• Negative Sentiment: Several other firms (Pomerantz, Bernstein Liebhard, Rosen, Robbins, Faruqi, Glancy, Levi & Korsinsky, Gross, Portnoy, etc.) have filed or circulated shareholder alerts and class‑action notices covering the same alleged class period (generally Mar. 26, 2025–Nov. 4, 2025). The proliferation of filings amplifies headline risk and increases the likelihood of consolidation, higher legal costs, and a prolonged overhang on the stock. Pomerantz alert

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.